Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma

NCT07654465 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma(MZL)

Interventions

DRUG: Rituximab
OTHER: Observation

Sponsor

Sun Yat-sen University